Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Randomized, Double-blind, Placebo-controlled Study of Ascending Doses of WVE-007 to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Adults Living with Overweight or Obesity

Next Previous
Trial Profile

A Phase 1, Randomized, Double-blind, Placebo-controlled Study of Ascending Doses of WVE-007 to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Adults Living with Overweight or Obesity

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs WVE 007 (Primary)
  • Indications Obesity; Overweight
  • Focus Adverse reactions; First in man; Proof of concept
  • Acronyms INLIGHT
  • Sponsors WaVe life Sciences

Most Recent Events

  • 09 Dec 2025 According to a Wave Life Sciences media release, company will announce interim data from this study.
  • 08 Dec 2025 According to a Wave Life Sciences media release, company will host an investor conference call today at 8:30 a.m. ET to review the INLIGHT Phase 1 interim clinical data.
  • 08 Dec 2025 According to a Wave Life Sciences media release, In the first quarter of 2026, Wave expects to deliver further follow-up (six-month) from the 240 mg single-dose cohort, as well as three-month follow-up data from the 400 mg single-dose cohort. In the second quarter of 2026, Wave expects to deliver six-month follow-up data from the 400 mg single-dose cohort and three-month follow-up data from the 600 mg single-dose cohort.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top